The Relationship among Pore-Size Ratings, Bubble Points, and Porosity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Relationship among Pore-Size Ratings, Bubble Points, and Porosity


Pharmaceutical Technology


References

1. T.H. Meltzer and M.W. Jornitz, Pharmaceutical Filtration: The Management of Organism Removal (DHI/PDA Publishers, Bethesda, MD, 2006).

2. US Food and Drug Administration, Center for Drugs and Biologics and Office of Regulatory Affairs, Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing: CGMP (FDA, Rockville, MD, 1987 and 2003).

3. F.W. Bowman, M.P. Calhoun, and M. White, "Microbiological Methods for Quality Control of Membrane Filters," J. Pharm. Sci. 56 (2), 222–225 (1967).

4. R.E. Kesting, "Synthetic Polymeric Membranes: A Structural Perspective," in Phase Inversion Membranes (Wiley-Interscience, New York, NY, 3d ed., 1985).

5. P.R. Johnston, Fluid Sterilization by Filtration (Interpharm/CDC, Boca Raton, FL, 2003), Chapters 1, 3, and 9.

6. H.W. Piekaar and L.A. Clarenburg, "Aerosol Filters: Pore Size Distribution in Fibrous Filters," Chem. Eng. Sci. 22, 1399–1408 (1967).

7. R.E. Williams and T.H. Meltzer, "Membrane Structure: The Bubble Point and Particle Retention: A New Theory," Pharm. Technol. 7 (5), 36–42 (1983).

8. F.J. Almgren and J.E. Taylor, "Geometry of Soap Films and Soap Bubbles," Sci. Amer. 235 (l), 82–93 (1976).

9. American Society for Testing and Materials, ASTM Standard F-316: Pore-Size Characteristics of Membrane Filters for Use with Aerospace Fluids (ASTM, West Conshohoken, PA, 1980).

10. T.H. Meltzer, "Chapter 3: Filter Porosity Characteristics," in Filtration in the Pharmaceutical Industry (Marcel Dekker, New York, NY, 1987), pp. 100–122.

11. E. Honold and E.L. Skau, "Application of Mercury-Intrusion Method for Determination of Pore-Size Distribution in Membrane Filters," Science 120, 805–806 (1954).

12. H.M. Rootare and J. Spencer, "A Computer Program for Pore Volume and Pore-Area Distribution Calculations from Mercury Porosimetry Data on Particulate and Porous Materials," Powder Technol . 6, 17–23 (1972).

13. R.E. Williams, Bubble Point Testing and Its Importance to the End User (Filtration Society, Monterey, CA, 1984).

14. J.K. Lee et al., "Pore Size Characteristics of Microporous Membrane Filters by Airflow Porosimetry and Particulate Loading Studies," Swiss Contam. Control 3, 160–164 (1990).

15. J.G. Zahka, "Pore Size Characteistics of Microporous Membranes and Filters by Airflow Porosimetry and Particulate Loading Studies," Swiss Contam. Control 3, 160–164 (1990).

16. B.G. Rogers and H.W. Rossmore, "Determination of Membrane Filter Porosity by Microbiological Methods," Devel. Indus. Microbiol. 2, 453–459 (1970).

17. K.H. Wallhäusser, "Is the Removal of Microorganisms by Filtration Really a Sterilization Method?" J. Paren. Drug Assoc. 33 (3), 156–171 (1979).

18. D.B. Pall, E.A. Kirnbauer, and B.T. Allen, "Particulate Retention by Bacteria Retentive Membrane Filters," Colloids and Surfaces 1, 25–35 (1980).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here